HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

RK-20449

an hematopoietic cell kinase inhibitor; structure in first source

Also Known As:

RK20449

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - RK-20449: 1
  - Pyrimidines: 510
    - RK-20449: 1

Experts

1.	Honma, Teruki: 1 article (01/2017)
2.	Kikuzato, Ko: 1 article (01/2017)
3.	Koda, Yasuko: 1 article (01/2017)
4.	Koyama, Hiroo: 1 article (01/2017)
5.	Kukimoto-Niino, Mutsuko: 1 article (01/2017)
6.	Mikuni, Junko: 1 article (01/2017)
7.	Shirai, Fumiyuki: 1 article (01/2017)
8.	Shirouzu, Mikako: 1 article (01/2017)
9.	Tanaka, Akiko: 1 article (01/2017)
10.	Tomabechi, Yuri: 1 article (01/2017)

Related Diseases

1.	Leukemia 01/01/2017 - "We previously reported the structure-based design of a highly potent hematopoietic cell kinase (HCK) inhibitor, a pyrrolo-pyrimidine compound designated RK-20449, for treatment of recurrent leukemia. "

Related Drugs and Biologics

1.	Proto-Oncogene Proteins c-hck
2.	pyrimidine